Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance

Circulation

Volumn 99, Issue 23, 1999, Pages 3050-3055

  Zhu, Yanhong ^a   Carmeliet, Peter ^b   Fay, William P ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Plasminogen activators; Platelets; Thrombolysis; Thrombosis

Indexed keywords

FERRIC CHLORIDE; HEPARIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOT LYSIS; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; FIBRINOLYTIC THERAPY; HISTOPATHOLOGY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; STRAIN DIFFERENCE;

EID: 0033564748     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.23.3050     Document Type: Article

References (36)

1. Jang I, Gold H, Ziskind A, Fallon J, Holt R, Leinbach R, May J, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation. 1989;79:920-928.
2. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
3. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988; 70:327-333.
4. Potter van Loon BJ, Rijken DC, Brommer EJP, Van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost. 1992;67:101-105.
5. Robbie LA, Bennett B, Croll AM, Brown PAJ, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost. 1996;75:127-133.
6. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res. 1993; 72:413-421.
7. Kunitada S, FitzGerald G, Fitzgerald D. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood. 1992;79:1420-1427.
8. Bajzar L, Tracy PB. Platelet factor V(a) is responsible for the majority of the antifibrinolytic effect of platelets. Blood. 1995;86:74a. Abstract.
9. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 1988;77:660-669.
10. Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis: study in healthy subjects and correlation with blood fibrinolytic parameters. Thromb Haemost. 1997;77:725-729.
11. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice, II: effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993;92:2756-2760.
12. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 1998;97:1002-1008.
13. Meyer BJ, Badimon JJ, Mailhac A, Fernandez-Ortiz A, Chesebro JH, Fuster V, Badimon L. Inhibition of growth of thrombus on fresh mural thrombus: targeting optimal therapy. Circulation. 1994;90:2432-2438.
14. Pislaru S, Pislaru C, Zhu X, Arnout J, Stassen T, Vanhove P, Herbert J-M, Meuleman DG, van de Werf F. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis. Thromb Haemost: 1998;79:1130-1135.
15. van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ. Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol. 1997;107:313-320.
16. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 dependent and independent mechanisms. Blood. 1994;83:351-356.
17. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
18. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor-1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombosis. Blood. 1993;81:1290-1299.
19. Stringer HAR, van Sweiten P, Heijnen H, Sixma J, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Arterioscler Thromb. 1994;14:1452-1458.
20. Huber K, Griffiths M, Schocher I, Sara M, Sleytr UB, Zasmeta G, Beckmann R, Zeiner A, Schreiber W, Binder BR. Comparison of a new rapid bedside assay for t-PA with a commercially available ELISA: possible importance of t-PA antigen determination during thrombolytic therapy for prediction of outcome. Fibrinolysis Proteolysis. 1998; 12(suppl 2): 102. Abstract.
21. Francis CW, Marder VJ. Physiologic regulation and pathologic disorders of fibrinolysis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: JB Lippincott Co; 1994:1076-1103.
22. Fay WP, Murphy JG, Owen WG. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi. Arterioscler Thromb Vasc Biol. 1996;16:1277-1284.
23. Friedman M, Van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am J Pathol. 1966;48:19-44.
24. Cockell KA, Ren S, Sun J, Angel A, Shen GX. Effect of thrombin on release of plasminogen activator inhibitor-1 from cultured primate arterial smooth muscle cells. Thromb Res. 1995;77:119-131.
25. Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation. 1990;82:1485-1493.
26. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation. 1995;91:1175-1181.
27. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981;46:561-565.
28. Lijnen HR, Van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem. 1994;224:863-871.
29. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993;88:1361-1374.
30. Friederich PW, Levi M, Biemond BJ, Charlton P, Templeton D, van Zonneveld AJ, Bevan P, Pannekoek H, ten Cate JW. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation. 1997;96:916-921.
31. Eitzman DT, Fay WP, Lawrence DA, Francis-Chmura AM, Shore JD, Olson ST, Ginsburg D. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest. 1995; 95:2416-2420.
32. Ohtani A, Murakami J, Hirano-Wakimoto A. T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats. Eur J Pharmacol. 1997;330:151-156.
33. van Giezen J, Wahlund G, Nerme V, Abrahamsson T. The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb Haemost. 1997;77:5:964-969.
34. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91:3670-3674.
35. Robbie LA, Booth NA, Croll AM, Bennett B. The roles of alpha-2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost. 1993;70:301-306.
36. Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly cross-linked alpha-polymer chains formed at high factor XIII concentrations. Blood. 1988;71:1361-1365.